ADMA Biologics, Inc. (ADMA)
Manufactures immune-boosting medications from donated blood plasma.
$8.79+0.04%Healthcare
StockGlow Score
Neutral
BearishBullish
1 year ago-54.5%
The outlook
ADMA sits near the low end of its 52-week range, with the average analyst target about 93% above the current price. Analyst coverage leans buy overall, though the stock is trading mixed relative to its moving averages. The valuation sits at a trailing P/E of 12.9, relatively modest for the biotech sector.
What’s behind the score
Analyst consensusBuy — 1.6 avg of 5 analysts
Price trendMixed vs its moving averages
52-week range12% of the way from its 52-week low to high
Price targetAvg target +93% vs current price
Analyst price target
~12-month · 5 analysts$17.00average target+93.4% vs now
Now $8.79
Low $12.00High $21.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$2.04B
52-wk high
$20.46
52-wk low
$7.21
50-day avg
$8.47
200-day avg
$13.46
Trailing P/E
12.9